The Aminoglycoside Family
2-DOS Ring Antibiotics — Decoding Site Binding and Resistance SAR
## Overview
Aminoglycoside antibiotics are polar, polycationic natural products produced by *Streptomyces* and *Micromonospora* species that have been used clinically since streptomycin in 1943. They are potent, rapidly bactericidal agents (unlike most other ribosome-targeting antibiotics, which are bacteriostatic) acting on the 30S ribosomal subunit to induce mRNA misreading. They remain critically important for serious Gram-negative infections (including resistant Pseudomonas, Acinetobacter, and carbapenem-resistant Enterobacteriaceae), especially in combination.
## Core Scaffold: 2-Deoxystreptamine
The unifying pharmacophore is the 2-deoxystreptamine (2-DOS) central ring, a cyclohexane with 1,3-amino groups and 4,5,6-hydroxyls. Flanking deoxy-amino sugars are attached at the 4-position (ring I, always a glucosamine derivative) and either the 5-position (4,5-class: neomycin, paromomycin) or the 6-position (4,6-class: gentamicin, tobramycin, kanamycin, amikacin). These two architectural classes contact overlapping but non-identical rRNA secondary structure elements.
## Decoding Site Mechanism and Bactericidal Killing
Aminoglycosides bind to the h44 helix of 16S rRNA at the A-site decoding center. Key contacts involve A1492 and A1493, which normally flip out during cognate tRNA recognition to check codon-anticodon geometry. Aminoglycoside binding locks A1492/A1493 in the flipped-out conformation, reducing the fidelity of tRNA selection—near-cognate tRNAs are accepted, introducing amino acid misincorporation into nascent protein chains. Critically, misfolded proteins are inserted into the bacterial membrane, disrupting membrane integrity and allowing increased aminoglycoside influx (the "self-perpetuating uptake" mechanism)—this explains bactericidal killing distinct from bacteriostatic ribosome-binding antibiotics.
## Ototoxicity and Nephrotoxicity
The clinical limitations of aminoglycosides are dose-limiting ototoxicity (irreversible cochlear and vestibular hair cell damage) and nephrotoxicity (proximal tubule cell accumulation via megalin/cubilin endocytosis). Cochlear hair cells express megalin, which concentrates aminoglycosides via receptor-mediated uptake. Once-daily dosing regimens (high peak, extended drug-free trough interval) exploit the concentration-dependent killing and post-antibiotic effect to maximize efficacy while reducing trough accumulation in hair cells. Mitochondrial 12S rRNA mutations (A1555G) dramatically increase ototoxicity risk—aminoglycosides bind the mitochondrial 12S rRNA, which resembles bacterial 16S rRNA at the decoding site.
## Resistance: Three Enzymatic Mechanisms
(1) **Aminoglycoside-modifying enzymes (AMEs)**: AAC (acetyltransferases), APH (phosphotransferases), ANT/AAD (nucleotidyltransferases) covalently modify specific amino and hydroxyl groups, abolishing ribosomal binding. (2) **16S rRNA methyltransferases (RMTs)**: armA, rmtA-H methylate A1408 or G1405 of h44, conferring pan-aminoglycoside resistance—the most clinically threatening mechanism. (3) **Efflux pumps**: MexXY-OprM in Pseudomonas reduces intracellular concentrations.
## Plazomicin: Next-Generation AME Evasion
Plazomicin was designed using the AME resistance map: a 1-N-HABA group (from amikacin) blocks AAC(6') and APH(2''), and an additional 6'-N-hydroxy group blocks AAC(6')-Ib. The combination protects against virtually all clinically relevant AMEs, restoring potency against isolates resistant to gentamicin, tobramycin, and amikacin. Plazomicin retains susceptibility only to RMT-expressing strains—a remaining clinical challenge.
## Key Takeaways
- The 2-DOS ring with 1,3-diamines is the universal pharmacophore; flanking amino-sugar rings extend contacts into the 16S rRNA decoding site
- Bactericidal killing arises from a self-perpetuating uptake cycle initiated by membrane protein misincorporation
- Ototoxicity relates to mitochondrial 12S rRNA similarity to bacterial 16S rRNA at the aminoglycoside binding site
- AME-mediated resistance guided rational modification: amikacin's 1-N-HABA and plazomicin's 6'-N-hydroxy block specific enzymes
- RMT-mediated pan-aminoglycoside resistance (armA) remains unsolved by current structural modifications
สรุป SAR
Key SAR findings for the aminoglycoside family:
- The 2-deoxystreptamine (2-DOS) ring is the universal pharmacophore; its 1,3-di-amino pattern makes key H-bonds to G1494 and C1495 of 16S rRNA at the A-site.
- The 4,5-disubstituted 2-DOS pattern (neomycin class) occupies helices h44 and h45; the 4,6-disubstituted pattern (gentamicin, tobramycin, amikacin) occupies h44 and h45 with different geometry.
- Hydroxyl and amino groups on ring I (the 4-position glucosamine) and ring III (5- or 6-position) make H-bond networks with A1408, A1492, A1493, and G1494 of h44.
- N-acylation of key amino groups by aminoglycoside acetyltransferases (AAC), phosphorylation by APHs, or adenylation by ANTs are the three enzymatic resistance mechanisms; modifications at specific positions predict resistance escape.
- Amikacin's 1-N-HABA (hydroxyaminobutyric acid) side chain sterically blocks the AAC(6') and APH(2'') enzymes responsible for most gentamicin/tobramycin resistance.
- Plazomicin (ACHN-490) adds both a 1-N-HABA and a 6'-N-hydroxy group, protecting against virtually all aminoglycoside-modifying enzymes except 16S rRNA methyltransferases (RMT).